[Edaravone: A New Treatment for ALS]

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Familial Amyotrophic Lateral Sclerosis (ALS) linked to SOD1 gene mutations suggests free radical injury in pathogenesis.
• Edaravone, a free radical scavenger, is approved for cerebral infarction in Japan.

Purpose of the Study:

• To discuss recent advancements in basic and clinical research for novel ALS treatments.
• To evaluate the therapeutic potential of edaravone in ALS patients.

Main Methods:

• Clinical trials involving ALS patients treated with edaravone.
• Review of basic and clinical research on ALS treatment development.

Main Results:

• Edaravone demonstrated a therapeutic effect in suppressing ALS symptom progression.
• Edaravone was approved as an ALS therapeutic agent in Japan in June 2015.

Conclusions:

• Free radical scavenging represents a viable therapeutic strategy for ALS.
• Ongoing research aims to develop new and improved treatments for ALS.